Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: 3SBio Inc. (NASDAQ: SSRX), AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), ANADIGICS, Inc. (NASDAQ: ANAD), PetroChina Company Ltd. (NYSE: PTR), and Teekay Corporation (NYSE: TK).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Wednesday’s Analyst Blog:

Buy 3SBio Up to $10

3SBio Inc. (NASDAQ: SSRX) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product EPIAO is the number 1 brand in China's EPO [erythropoietin] market.

Its second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deal with US-based AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) will boost its expansion into IV Iron market.

Anadigics a Hold on Guidance

ANADIGICS, Inc. (NASDAQ: ANAD) designs and manufactures radio frequency integrated circuits (ICs) for the wireless and broadband markets. Anadigics earlier reported revenues of $45.2 million in Q4:08, down 33.0% year over year and down 22.1% quarter over quarter.

Going forward, ANAD expects a decline of 35% year over year in Q1:09. In addition, the under-utilization of fabs will put pressure on gross margins. Management also stated that the fab is under-utilized and the company is not starting a lot of wafers due to the inventory position at the end of Q4. The company is looking for inventory turns above five in the coming quarter.

PetroChina Remains Expensive

PetroChina Company Ltd. (NYSE: PTR) is the largest integrated oil company in China. The company's activities include: the exploration, development, production and sale of crude oil and natural gas; the refining, transportation, storage and marketing of petroleum products; the manufacture and sale of chemical products; and the transmission of natural gas, crude oil and refined products.

PetroChina ADRs have been weak in recent days, in line with the rest of the group, due to the pullback in crude oil prices and the broad turmoil in global markets. But they are hardly cheap. Based on most conventional valuation metrics, the ADRs are currently trading at a premium to the Chinese and other emerging market peers.

Teekay Shipping Stays Afloat

We are maintaining our Hold on Teekay Corporation (NYSE: TK), but reducing our target price to $15. TK reported 3rd quarter EPS of $1.29 before nonrecurring items, above consensus and our estimate of $1.12, largely reflecting higher-than-expected revenue growth.

We are cutting our 2008 diluted EPS estimate to $3.75 from $4.00, as well as our 2009 estimate to $1.15 from $2.75, as we have moderated our revenue assumptions. Results should reflect the impact of global economic weakening on both spot rates and shipping volumes. We note that TK released restated financial results for the first half related to changes in the accounting treatment for long-term incentive compensation.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.